June 2009
Market Update: At a Fork in the Road
June 15, 2009
Last week I took a pretty detailed look at how the market - the S&P 500 in this case - wasn't exactly as bearish as everyone thought it might be, but was instead simply trapped in a range... between 926 and 950. Though I was generally bearish, I had no real 'supporting evidence' for my thesis. I...
Last week I took a pretty detailed look at how the market - the S&P 500 in this case - wasn't exactly as bearish as everyone thought it might be, but was instead simply trapped in a range... between 926 and 950. Though I was generally bearish, I had no real 'supporting evidence' for my thesis. I...
January 2009
Obama & Co. to Turn Pharma Switch 'On'?
January 10, 2009
When we published our recommendation of CEL-SCI (AMEX: CVM) shares on Wednesday morning of this week, we really had no idea some of you would be able to exit at our target price of 40 cents by Thursday afternoon. I've triple-checked it since then though, and it's true - there were a few transactions...
When we published our recommendation of CEL-SCI (AMEX: CVM) shares on Wednesday morning of this week, we really had no idea some of you would be able to exit at our target price of 40 cents by Thursday afternoon. I've triple-checked it since then though, and it's true - there were a few transactions...
Big Pharma's Paradigm Shift = Biotech Investment Opportunity
January 07, 2009
With both the market and the economy apparently poised to begin improving, I know we're all interested in trading ideas that will start the portfolio-recovery process. What's interesting about today's idea, though, is how the bear market may have actually obscured the opportunity's development. Today...
With both the market and the economy apparently poised to begin improving, I know we're all interested in trading ideas that will start the portfolio-recovery process. What's interesting about today's idea, though, is how the bear market may have actually obscured the opportunity's development. Today...
March 2008
Do Or Die Time For Stocks - What To Look For
March 08, 2008
No small cap suggestion for today, which is fine actually ...there are more important things to talk about after Friday's bearish end to an even more bearish week. The last time we looked, all the indices were toying with another breakdown. We pretty much got to the proverbial fork in the road after...
No small cap suggestion for today, which is fine actually ...there are more important things to talk about after Friday's bearish end to an even more bearish week. The last time we looked, all the indices were toying with another breakdown. We pretty much got to the proverbial fork in the road after...
December 2007
Small Cap Network - Cleaning House For 2008
December 20, 2007
The end of the year is right around the corner, and I for one am glad. We've been itching to close the books on a handful of our followings, and perhaps benefit from a tax loss (since they didn't benefit us in many other ways). At the same time, there are also a few names we want to be sure to keep...
The end of the year is right around the corner, and I for one am glad. We've been itching to close the books on a handful of our followings, and perhaps benefit from a tax loss (since they didn't benefit us in many other ways). At the same time, there are also a few names we want to be sure to keep...
November 2007
Lock in Gold Gain, Biotech Trade Still 'Brewing'
November 03, 2007
We've got updates on today on three of our prior trading ideas. One's about an idea that went well enough to lock in a decent gain, the next is about an idea that went not-so-well (so far), and the last look is at a longer-term idea that's still brewing up. So, odds are at least part of today's newsletter...
We've got updates on today on three of our prior trading ideas. One's about an idea that went well enough to lock in a decent gain, the next is about an idea that went not-so-well (so far), and the last look is at a longer-term idea that's still brewing up. So, odds are at least part of today's newsletter...
October 2007
Big Pharma, Small Biotech - Who Needs Who?
October 20, 2007
Sometimes picking a small cap stock is about the numbers and certainty. Other times there's a little philosophy to it. I think both are important. Today we've got some philosophical answers to questions many of you have been voicing about biotech R&D company CEL-SCI Corporation (AMEX: CVM). This...
Sometimes picking a small cap stock is about the numbers and certainty. Other times there's a little philosophy to it. I think both are important. Today we've got some philosophical answers to questions many of you have been voicing about biotech R&D company CEL-SCI Corporation (AMEX: CVM). This...
April 2007
A Handful of Looming Breakouts
April 29, 2007
Something a little different today. After Wednesday's look at the likely summertime strength in small caps, I thought it would be fitting to study which of our profiled companies seemed technically best-poised to take advantage of the tendency. After all, not every stock can go higher - I've always tried...
Something a little different today. After Wednesday's look at the likely summertime strength in small caps, I thought it would be fitting to study which of our profiled companies seemed technically best-poised to take advantage of the tendency. After all, not every stock can go higher - I've always tried...
Locked & Loaded - CVM Finds Funding
April 18, 2007
When someone hands over $15 million to a biotech company to continue work on a cancer treatment, I have to take notice. Some of the underlying meanings I interpret in a transaction of this size include the notions that (1) the drug has enough merit so far to keep developing it, and (2) the company has...
When someone hands over $15 million to a biotech company to continue work on a cancer treatment, I have to take notice. Some of the underlying meanings I interpret in a transaction of this size include the notions that (1) the drug has enough merit so far to keep developing it, and (2) the company has...
March 2007
Could CEL-SCI Be A Lucky Charm?
March 17, 2007
Happy Saint Patrick's Day! If you're wishing for the luck o' the Irish to work its way into your stock trading, we may have a lucky charm for you today. Gratuitous Saint Patrick's Day clichés aside..... As we mentioned in the blog a couple of days ago, CEL-SCI Corporation (AMEX:CVM) has a new...
Happy Saint Patrick's Day! If you're wishing for the luck o' the Irish to work its way into your stock trading, we may have a lucky charm for you today. Gratuitous Saint Patrick's Day clichés aside..... As we mentioned in the blog a couple of days ago, CEL-SCI Corporation (AMEX:CVM) has a new...
January 2007
FDA Grants Phase III Approval for CEL-SCI's Multikine
January 16, 2007
Remember a couple of weeks ago when we discussed how CEL-SCI Corporation (AMEX: CVM) had been unusually quiet of late? Knowing what we know about the company, we just figured something big was brewing and the news would be released seemingly out of nowhere, like a bolt of lightning. Well, it seems we...
Remember a couple of weeks ago when we discussed how CEL-SCI Corporation (AMEX: CVM) had been unusually quiet of late? Knowing what we know about the company, we just figured something big was brewing and the news would be released seemingly out of nowhere, like a bolt of lightning. Well, it seems we...
Can Lightning Strike Twice?
January 05, 2007
Remember the cliché 'Expect it when you least expect it'? Technically it's impossible to do, yet it's still valuable advice even within the investing world. We think we're seeing this kind of scenario develop with shares of CEL-SCI Corporation (AMEX: CVM). Except for December's eye-popping news...
Remember the cliché 'Expect it when you least expect it'? Technically it's impossible to do, yet it's still valuable advice even within the investing world. We think we're seeing this kind of scenario develop with shares of CEL-SCI Corporation (AMEX: CVM). Except for December's eye-popping news...
December 2006
2006 in Review, Plans for 2007
December 27, 2006
Well it's that time of year again - a chance to look back, reflect, and then clean the slate for a new calendar year. We're particularly excited about 2007 because of some major ideas we're already working on for the SmallCap Digest (though you'll have to be patient in the meantime). Yet, we'd be amiss...
Well it's that time of year again - a chance to look back, reflect, and then clean the slate for a new calendar year. We're particularly excited about 2007 because of some major ideas we're already working on for the SmallCap Digest (though you'll have to be patient in the meantime). Yet, we'd be amiss...
September 2006
A Heart To Heart Chat With a Biotech CEO
September 22, 2006
We recently sat down with CEL-SCI Corporation (AMEX: CVM) CEO Geert Kersten to discuss his recent letter to shareholders, the company's stock price, and what the future might hold. And, what we learned went well beyond the usual corporate PR stuff. Investors (potential or current) take note...this is...
We recently sat down with CEL-SCI Corporation (AMEX: CVM) CEO Geert Kersten to discuss his recent letter to shareholders, the company's stock price, and what the future might hold. And, what we learned went well beyond the usual corporate PR stuff. Investors (potential or current) take note...this is...
August 2006
CEL-SCI's Operating Fund Pool Gets Refilled
August 07, 2006
Great news for CEL-SCI (AMEX: CVM) today - the company just announced a financing deal that's going to provide a major injection of working capital. Plus, the terms of the deal are about as sweet - and flexible - as any company could ask for. In short, CEL-SCI has garnered $8.3 million worth of working...
Great news for CEL-SCI (AMEX: CVM) today - the company just announced a financing deal that's going to provide a major injection of working capital. Plus, the terms of the deal are about as sweet - and flexible - as any company could ask for. In short, CEL-SCI has garnered $8.3 million worth of working...
May 2006
CEL-SCI Delivers Positive Data
May 24, 2006
We’ve been covering CEL-SCI (AMEX: CVM) off and on now for almost four years. Both times we initiated coverage, first back in November of ’02 and again in February of this year, the stock went on to reward our readers substantially for the year. Therefore, we like to think we have come to know this story...
We’ve been covering CEL-SCI (AMEX: CVM) off and on now for almost four years. Both times we initiated coverage, first back in November of ’02 and again in February of this year, the stock went on to reward our readers substantially for the year. Therefore, we like to think we have come to know this story...
April 2006
Cel-Sci's Target Price Raised
April 25, 2006
As we noted on the SCBLOG Monday afternoon, Midas Research of Germany released a comprehensive 16-page follow-up report on biotech CEL-SCI (AMEX: CVM). As a result of recent corporate news and developments, Midas has raised its 12-month target for CVM shares to $3.71 versus $2.80 as noted in its previous...
As we noted on the SCBLOG Monday afternoon, Midas Research of Germany released a comprehensive 16-page follow-up report on biotech CEL-SCI (AMEX: CVM). As a result of recent corporate news and developments, Midas has raised its 12-month target for CVM shares to $3.71 versus $2.80 as noted in its previous...
Profit From eCommerce. Now.
April 08, 2006
Since we profiled eCommerce technology firm NeWave (OTCBB: NWWV) on March 22nd at 19 cents, the Company has been anything but idle. (Have a read of our piece for a detailed background). This Company, in our opinion, is poised for significant ongoing success and firmly on...
Since we profiled eCommerce technology firm NeWave (OTCBB: NWWV) on March 22nd at 19 cents, the Company has been anything but idle. (Have a read of our piece for a detailed background). This Company, in our opinion, is poised for significant ongoing success and firmly on...
Profits Come Out of the Closet
April 03, 2006
Profits Come Out of the Closet Weary of the vagaries of tech and biotech? For savvy Investors who want solid, virtually guaranteed growth, you need quality equity exposure to footwear - specifically the significant mass market potential for women's designer footwear. The following investment idea could...
Profits Come Out of the Closet Weary of the vagaries of tech and biotech? For savvy Investors who want solid, virtually guaranteed growth, you need quality equity exposure to footwear - specifically the significant mass market potential for women's designer footwear. The following investment idea could...
February 2006
CEL-SCI Rockets Higher
February 28, 2006
CEL-SCI Rockets Higher. Pre-opening, Tuesday, biotech CEL-SCI (AMEX: CVM) traded up to 92 cents. We Alerted the readership a scant two weeks ago when the shares were idling at 52-cents. At this writing the shares are trading strongly at 84-85 cents on significant volume—a rise of over 60 percent since...
CEL-SCI Rockets Higher. Pre-opening, Tuesday, biotech CEL-SCI (AMEX: CVM) traded up to 92 cents. We Alerted the readership a scant two weeks ago when the shares were idling at 52-cents. At this writing the shares are trading strongly at 84-85 cents on significant volume—a rise of over 60 percent since...
Feature: The Key to Defeating Cancer; Increasing Survival Rates.
February 21, 2006
Feature: The Key to Defeating Cancer; Increasing Survival Rates. The bottom line to successful cancer treatment is relatively straightforward: the longer this deadly scourge can be held at bay or put into remission, the better a patient’s chance of survival. That’s a concept Big Pharma, which tends...
Feature: The Key to Defeating Cancer; Increasing Survival Rates. The bottom line to successful cancer treatment is relatively straightforward: the longer this deadly scourge can be held at bay or put into remission, the better a patient’s chance of survival. That’s a concept Big Pharma, which tends...
Trading Alert: Get This Biotech Before A Breakout.
February 10, 2006
Trading Alert: Get This Biotech Before A Breakout. We first alerted the readership to a unique biotech company, CEL-SCI (AMEX: CVM), in November 2002 at 21 cents. The shares of this proprietary cancer/disease therapeutics company are exceptional traders and during our coverage period readers had several...
Trading Alert: Get This Biotech Before A Breakout. We first alerted the readership to a unique biotech company, CEL-SCI (AMEX: CVM), in November 2002 at 21 cents. The shares of this proprietary cancer/disease therapeutics company are exceptional traders and during our coverage period readers had several...
June 2005
Feature: Biotech - The Next Big Boom?
June 14, 2005
Feature: Biotech - The Next Big Boom? For the most part, Biotech companies don’t trade on fundamentals. They are trade on the three ‘P’s”: potential, pipeline and vision. OK, two p’s and a v. Even senior companies’ prices--such as Genentech (NYSE: DNA) --look positively goofy if you try to rationalize...
Feature: Biotech - The Next Big Boom? For the most part, Biotech companies don’t trade on fundamentals. They are trade on the three ‘P’s”: potential, pipeline and vision. OK, two p’s and a v. Even senior companies’ prices--such as Genentech (NYSE: DNA) --look positively goofy if you try to rationalize...
March 2004
Feature: Cel-Sci - Got Shares?
March 30, 2004
Feature: Cel-Sci - Got shares? Upon release of an extensive research report, Monday, the shares of biotech company Cel-Sci (AMEX: CVM) moved up almost 20 percent. The report by Midas Research, an independent German Research company, is available for free download (in English) at www.midasresearch.de...
Feature: Cel-Sci - Got shares? Upon release of an extensive research report, Monday, the shares of biotech company Cel-Sci (AMEX: CVM) moved up almost 20 percent. The report by Midas Research, an independent German Research company, is available for free download (in English) at www.midasresearch.de...
February 2004
Feature: NASDAQ Tightens, Imclone Brightens and Homeland Heightens.
February 13, 2004
Feature: NASDAQ tightens, Imclone brightens and Homeland heightens. Since today is Friday the 13th, tomorrow, Valentine’s Day—also known as male atonement day—and Monday, the President’s Day holiday, I thought we’d drive-by a few topics and visit a selection of stocks that we cover. And, being a full...
Feature: NASDAQ tightens, Imclone brightens and Homeland heightens. Since today is Friday the 13th, tomorrow, Valentine’s Day—also known as male atonement day—and Monday, the President’s Day holiday, I thought we’d drive-by a few topics and visit a selection of stocks that we cover. And, being a full...
January 2004
Feature: Spectrum Sciences snags major defense contract. Market Notes.
January 07, 2004
Feature: Spectrum Sciences snags major defense contract. Market Notes. As noted here several times over the last few weeks, we expect Spectrum Sciences (OTCBB: SPSC) to have a robust 2004, punctuated by many new contract announcements. How’s this one to kick off the New Year? Spectrum has secured a...
Feature: Spectrum Sciences snags major defense contract. Market Notes. As noted here several times over the last few weeks, we expect Spectrum Sciences (OTCBB: SPSC) to have a robust 2004, punctuated by many new contract announcements. How’s this one to kick off the New Year? Spectrum has secured a...
December 2003
Feature: C-Chip means security. Cel-Sci: peer reviewed.
December 08, 2003
Features: C-Chip means security. Cel-Sci: peer reviewed. Sitting around waiting for the holidays? Well, C-Chip Technologies (OTCBB: CCHI) isn’t. The company’s doing deals. In one fell swoop, Friday, this supplier of proprietary asset and security management products (see our Trading Alert) has become...
Features: C-Chip means security. Cel-Sci: peer reviewed. Sitting around waiting for the holidays? Well, C-Chip Technologies (OTCBB: CCHI) isn’t. The company’s doing deals. In one fell swoop, Friday, this supplier of proprietary asset and security management products (see our Trading Alert) has become...
October 2003
What's driving CEL-SCI higher?
October 14, 2003
What’s driving CEL-SCI higher? Biotech company CEL-SCI (AMEX: CVM) closed at $1.36, Monday. When we mentioned, on September 5th, that the shares had likely bottomed, they were trading at 72 cents. The 52-week high is right here--$1.36. Technically, if that level is breached with conviction, the shares...
What’s driving CEL-SCI higher? Biotech company CEL-SCI (AMEX: CVM) closed at $1.36, Monday. When we mentioned, on September 5th, that the shares had likely bottomed, they were trading at 72 cents. The 52-week high is right here--$1.36. Technically, if that level is breached with conviction, the shares...
July 2003
CEL-SCI: Of Patents, Peer reviews and Milestones met.
July 14, 2003
CEL-SCI: Of Patents, Peer reviews and Milestones met. At the beginning of 2003, CEL-SCI (AMEX: CVM) CEO Geert Kersten outlined a series of corporate milestones for the year. Goal: Attract $1 million in grants. Result: $1.4 million attracted year-to-date as well as an extensive collaborative research...
CEL-SCI: Of Patents, Peer reviews and Milestones met. At the beginning of 2003, CEL-SCI (AMEX: CVM) CEO Geert Kersten outlined a series of corporate milestones for the year. Goal: Attract $1 million in grants. Result: $1.4 million attracted year-to-date as well as an extensive collaborative research...
June 2003
CEL-SCI: Of Patents and Partners
June 25, 2003
CEL-SCI: Of Patents and Partners CEL-SCI (AMEX: CVM) has had a wild week and it's only Wednesday. After dropping from north of $1 last week to a bottom of 67 cents Monday, the shares shot back to the mid-90-cent range that same day. Currently, the shares are trading around 95 cents, Wednesday, on growing...
CEL-SCI: Of Patents and Partners CEL-SCI (AMEX: CVM) has had a wild week and it's only Wednesday. After dropping from north of $1 last week to a bottom of 67 cents Monday, the shares shot back to the mid-90-cent range that same day. Currently, the shares are trading around 95 cents, Wednesday, on growing...
Itinerant Market Musings
June 18, 2003
Itinerant Market Musings There's a bunch of topics to cover this week. First and foremost, whither the NASDAQ now that it's roiling around at the high end of the trading range we laid out in March? Just about everyone and their dog is looking for a pullback now that the markets have run. With the NASDAQ...
Itinerant Market Musings There's a bunch of topics to cover this week. First and foremost, whither the NASDAQ now that it's roiling around at the high end of the trading range we laid out in March? Just about everyone and their dog is looking for a pullback now that the markets have run. With the NASDAQ...
CEL-SCI : The timing looks right.
June 03, 2003
CEL-SCI : The timing looks right. On November 8th, 2002, we introduced you, by way of a Trading Alert, to biotech CEL-SCI (AMEX: CVM) which, at the time, was trading at a scant 21 cents a share. On Tuesday the shares opened at 79 cents and closed at nearly $1, an almost 400% increase since we initiated...
CEL-SCI : The timing looks right. On November 8th, 2002, we introduced you, by way of a Trading Alert, to biotech CEL-SCI (AMEX: CVM) which, at the time, was trading at a scant 21 cents a share. On Tuesday the shares opened at 79 cents and closed at nearly $1, an almost 400% increase since we initiated...
May 2003
Cancer Therapies, Selling on History and the BIG NASD(y) picture.
May 09, 2003
Cancer Therapies, selling on history and the big NASD(y) picture. When SmallCap Digest first looked at biotech Cel-SCI (CVM: AMEX) at the beginning of 2003, it was trading at 18-20 cents. We felt that once the shares breached 28-30 cents, a new up-trend would emerge. Well, the shares have rocketed of...
Cancer Therapies, selling on history and the big NASD(y) picture. When SmallCap Digest first looked at biotech Cel-SCI (CVM: AMEX) at the beginning of 2003, it was trading at 18-20 cents. We felt that once the shares breached 28-30 cents, a new up-trend would emerge. Well, the shares have rocketed of...
April 2003
CEL-SCI --The Quest for Immunization against Bio-Terrorism
April 04, 2003
CEL-SCI --The Quest for Immunization against Bio-Terrorism Lots of exciting developments at biotech firm CEL-SCI Corp (CVM: AMEX), both in product development and research funding. CEL-SCI Corp's development of its CEL-1000 compound as a possible drug/vaccine against multiple bio-terrorism agents took...
CEL-SCI --The Quest for Immunization against Bio-Terrorism Lots of exciting developments at biotech firm CEL-SCI Corp (CVM: AMEX), both in product development and research funding. CEL-SCI Corp's development of its CEL-1000 compound as a possible drug/vaccine against multiple bio-terrorism agents took...
January 2003
Cel-Sci Corp. in the News!
January 10, 2003
Cel-Sci in the News Today, just after the market closed, Cel-Sci Corporation announced its year end financial results. In conjunction, the company announced an additional round of financing for $1.35 million, which will provide enough working capital for another year and allow the company to pursue...
Cel-Sci in the News Today, just after the market closed, Cel-Sci Corporation announced its year end financial results. In conjunction, the company announced an additional round of financing for $1.35 million, which will provide enough working capital for another year and allow the company to pursue...
November 2002
CEL-SCI Enters Into Collaboration With Proxima Concepts
November 18, 2002
CEL-SCI Enters Into Collaboration With Proxima Concepts. CEL-SCI (CVM), our November profile has entered into an agreement with Proxima Concepts, a firm out of London, to develop oral formulation of CEL-SCI's new compound CEL-1000. This latest development marks the third partner for CEL-SCI's CEL-1000...
CEL-SCI Enters Into Collaboration With Proxima Concepts. CEL-SCI (CVM), our November profile has entered into an agreement with Proxima Concepts, a firm out of London, to develop oral formulation of CEL-SCI's new compound CEL-1000. This latest development marks the third partner for CEL-SCI's CEL-1000...
November Profile: CEL-SCI Corporation (AMEX:CVM)
November 08, 2002
November Profile: CEL-SCI Corporation (AMEX:CVM) On March 3, 1995 a little known biotech company named Imclone Systems (IMCL) closed at $0.19 per share (a split adjusted price of $0.38 per share). Over the course of the next seven years this biotechnology company began an incredible run that may never...
November Profile: CEL-SCI Corporation (AMEX:CVM) On March 3, 1995 a little known biotech company named Imclone Systems (IMCL) closed at $0.19 per share (a split adjusted price of $0.38 per share). Over the course of the next seven years this biotechnology company began an incredible run that may never...
